15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 9 firms covering Fulcrum Therapeutics Inc, 1 rate it Buy or better, 5 sit at Hold, and 3 rate it Sell or worse, a moderate sell consensus. The target range is very wide, $3.00 to $24.00 (about 8.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $8.67 sits 127% above the current $3.82. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.06 next quarter toward $-0.49 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS9 ratings
Moderate Sell
Strong Buy00%
Buy111%
Hold556%
Sell333%
Strong Sell00%
Based on 9 analysts giving stock ratings to Fulcrum Therapeutics Inc.
As of Sep, 1 of 9 firms rate FULC a Buy (5 Hold, 3 Sell), the standing distribution of every covering firm's most recent active call.
FULC EPS & revenue forecast
EPS · NEXT QUARTER
$-0.06
Range $-0.08 – $-0.05 · 3 analysts · -79% YoY
Next period, 3 analysts expect Fulcrum Therapeutics Inc to earn $-0.06 a share (range $-0.08 – $-0.05), versus $-0.31 a year earlier. Full-year consensus is $-0.66, growing to $-0.49 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 3 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Fulcrum Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on FULC.
#1
Luca Issi
RBC Capital · Rank #1
Hold
$4.00+4.7% to target
Overall win rate
55%
+ Follow
#2
Andrew Fein
HC Wainwright & Co. · Rank #55
Hold
$3.00-21.5% to target
Overall win rate
46%
+ Follow
#3
Anupam Rama
JP Morgan · Rank #75
Sell
No targeton FULC
Overall win rate
51%
+ Follow
#4
Kristen Kluska
Cantor Fitzgerald · Rank #169
Buy
$24.00+528.3% to target
Overall win rate
38%
+ Follow
#5
Gregory Renza
RBC Capital · Rank #213
Hold
$4.00+4.7% to target
Overall win rate
34%
+ Follow
FULC stock forecast FAQ
What is FULC's average 12-month price target?+
The 8 analysts with a live target average $8.67 for Fulcrum Therapeutics Inc over the next 12 months, ranging from a $24.00 high to a $3.00 low.
Is FULC stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Sell. Of the 9 analyst ratings, 1 are Buy or Strong Buy, 5 are Hold, and 3 are Sell or Strong Sell.
What are the highest and lowest price targets for FULC?+
The Street-high target is $24.00 (Cantor Fitzgerald), and the Street-low is $3.00 (Stifel). The average of all 8 active targets is $8.67.
How many Wall Street analysts cover FULC?+
9 analysts have an active rating on Fulcrum Therapeutics Inc, and 8 firms carry a live 12-month price target.
Who is the most accurate analyst covering FULC?+
Among analysts who currently cover FULC, Luca Issi of RBC Capital has the strongest overall Quantellect track record (Rank #1). Their current call is Hold with a $4.00 target.
What is Fulcrum Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.06 per share (range $-0.08 – $-0.05) across 3 analysts. Full-year EPS is projected at $-0.66, rising to $-0.49 the following year.
How much revenue is Fulcrum Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading FULC lately?+
As of Sep, 1 of 9 firms rate FULC a Buy (5 Hold, 3 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their FULC calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
